HIC ZBTB transcriptional repressor 2Genealiases: HRG22 · ZBTB30 · ZNF907
Q-omics provides the consensus-scored HIC2 profile across patient tissues and cancer cell-line models. HIC2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HIC2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, HIC2 RNA expression shows 21,020 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where HIC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIC2 survival associations across molecular data types. HIC2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIC2 RNA expression–survival associations across cancer types. High HIC2 expression shows unfavorable associations in ACC, LIHC and LUSC, but favorable associations in READ, KIRC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HIC2 RNA expression.
This table summarizes HIC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HIC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIC2 shows lower tumor expression in THCA and higher tumor expression in LIHC, BLCA, STAD, HNSC and KIRC. The THCA box plot shows higher HIC2 RNA expression in normal versus tumor tissue (log2 FC = −1.104, t-test p < 0.001).
This table shows molecular features associated with HIC2 in patient tissues and cancer cell lines. In patient samples, HIC2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HIC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
